Glenmark Pharmaceuticals Inc., the United States-based subsidiary of Glenmark Pharmaceuticals Limited, announced the launch of Lacosamide Injection USP on June 5, 2026. The product, available in 200 mg/20 mL (10 mg/mL) single-dose vials, is bioequivalent and therapeutically equivalent to the reference listed drug Vimpat Injection, marketed by UCB, Inc. This launch expands the company's injectable portfolio in the North American market.

According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market achieved annual sales of approximately $15.2 million. This figure represents the total market sales including the brand and all available therapeutic equivalents. Glenmark's product is approved specifically for the indications listed in its approved label.

Marc Kikuchi, President & Business Head of North America, stated that the launch reflects the disciplined execution of the company's strategy to build a broader product portfolio. He emphasized that expanding the injectable range enhances the ability to meet healthcare providers' needs while improving patient access to affordable treatment options.

The following table outlines the key product details:

Glenmark Pharmaceuticals Limited is a research-led pharmaceutical company with a commercial footprint in over 80 countries. The company focuses on innovation and accessibility across branded, generics, and consumer health products.

Glenmark Pharmaceuticals has uploaded the transcript of its earnings call for the fourth quarter and year ended March 31, 2026. The conference call was held on Monday, June 01, 2026, and the transcript is now accessible on the company's website. This disclosure was made pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Earnings Call Transcript

The management discussed the company's performance for Q4 and the full fiscal year FY26 during the call. The transcript document provides a detailed record of the proceedings.

Regulatory Compliance

The submission confirms the availability of the transcript on the company's website. The communication was addressed to the National Stock Exchange of India Limited and BSE Limited, providing the necessary reference numbers and ISIN details for the scrip. The filing was submitted by Rashmi Khandelwal, Company Secretary & Compliance Officer.